Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children

Journal of the American Academy of Dermatology

Volumn 47, Issue 4, 2002, Pages 548-552

  Tristani Firouzi, Payam ^a   Petersen, Marta J ^a   Saffle, Jeffrey R ^a   Morris, Stephen E ^a   Zone, John J ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOBRANE; CARBAMAZEPINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ERYTHROMYCIN; IMMUNOGLOBULIN; LAMOTRIGINE; PENICILLIN G; PHENOBARBITAL; PHENYTOIN; SULFAFURAZOLE; THALIDOMIDE;

ADOLESCENT; ADULT; ANAPHYLAXIS; ARTICLE; BACTEREMIA; BODY SURFACE; CLINICAL ARTICLE; CLINICAL FEATURE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DEBRIDEMENT; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; EPITHELIZATION; FEMALE; HEADACHE; HEMOLYSIS; HOSPITALIZATION; HUMAN; IMMUNOTHERAPY; INFECTION; LENGTH OF STAY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORAXELLA; MORTALITY; NAUSEA; NEPHROSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SEPSIS; SKIN TRANSPLANTATION; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; WOUND DRESSING; XENOGRAFT;

EID: 0036788797     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.127249     Document Type: Article

References (26)

1. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7.
2. Wolkenstein P, Revuz J. Toxic epidermal necrolysis. Dermatol Clin 2000;18:485-95, ix.
3. Taylor JA, Grube B, Heimbach DM, Bergman AB. Toxic epidermal necrolysis. A comprehensive approach. Multidisciplinary management in a burn center. Clin Pediatr (Phila) 1989;28:404-7.
4. Yarbrough DR 3rd. Experience with toxic epidermal necrolysis treated in a burn center. J Burn Care Rehabil 1996;17:30-3.
5. Arevalo JM, Lorente JA, Gonzalez-Herrada C, Jimenez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 2000;48:473-8.
6. Paquet P, Pierard GE. Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis? Dermatology 1999;198:198-202.
7. Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352:1586-9.
8. Egan CA, Grant WJ, Morris SE, Saffle JR, Zone JJ. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999;40:458-61.
9. Kamanabroo D, Schmitz-Landgraf W, Czarnetzki BM. Plasmapheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol 1985;121:1548-9.
10. Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986;204:503-12.
11. Smoot EC 3rd. Treatment issues in the care of patients with toxic epidermal necrolysis. Burns 1999;25:439-42.
12. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-9.
13. Gottfried I, Seeber A, Anegg B, Rieger A, Stingl G, Volc -Platzer B. High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels. Eur J Dermatol 2000;10:29-35.
14. Dalakas MC, Ilia I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000.
15. Rutter A, Luger TA. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol 2001;44:1010-24.
16. iard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-3.
17. Sanwo M, Nwadiuko R, Beall G. Use of intravenous immunoglobulin in the treatment of severe cutaneous drug reactions in patients with AIDS. J Allergy Clin Immunol 1996;98:1112-5.
18. Phan TG, Wong RC, Crotty K, Adelstein S. Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin. Australas J Dermatol 1999; 40:153-7.
19. Magina S, Lisboa C, Goncalves E, Conceicao F, Leal V, Mesquita-Guimaraes J. A case of toxic epidermal necrolysis treated with intravenous immunoglobin. Br J Dermatol 2000;142:191-2.
20. Paul C, Wolkenstein P, Adle H, Wechsler J, Garchon HJ, Revuz J, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996;134:710-4.
21. Colsky AS. Intravenous immunoglobulin in autoimmune and inflammatory dermatoses. A review of proposed mechanisms of action and therapeutic applications. Dermatol Clin 2000;18:447-57, ix.
22. Sheridan RL, Weber JM, Schulz JT, Ryan CM, Low HM, Tompkins RG. Management of severe toxic epidermal necrolysis in children. J Burn Care Rehabil 1999;20:497-500.
23. Prendiville JS, Hebert AA, Greenwald MJ, Esterly NB. Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr 1989;115:881-7.
24. Revuz J, Penso D, Roujeau JC, Guillaume JC, Payne CR, Wechsler J, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987;123:1160-5.
25. Ruiz-Maldonado R. Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases. J Am Acad Dermatol 1985; 13:623-35.
26. Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992;339:662-4.